MedTrace Logo

Auto-injector Real Life Handling in Patients

NCT04224194 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 107

Last updated 2022-05-05

No results posted yet for this study

Summary

To assess the real-life patient handling experience with the use of an autoinjector in patients with moderate to severe active Rheumatoid Arthritis (RA) who self-inject AVT02 subcutaneously (SC).

Conditions

Interventions

COMBINATION_PRODUCT

Adalimumab

Combined product as Drug is delivered through an autoinjector pen on which real-life patient handling experience is assessed.

Sponsors & Collaborators

  • Alvotech Swiss AG

    lead INDUSTRY

Principal Investigators

  • Nemanja Damjanov, Prof · University School of Medicine, Dir. Inst. of Rheumatology, Belgrade

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-04
Primary Completion
2020-07-08
Completion
2021-02-26

Countries

  • Georgia
  • Ukraine

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04224194 on ClinicalTrials.gov